{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:51:27Z","timestamp":1780415487868,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Long\u2010term follow\u2010up (\u22654\u00a0years) demonstrated a low incidence of cardiac and vascular treatment\u2010emergent adverse events (TEAEs) with bosutinib treatment. We evaluated cardiac, vascular, hypertension, and effusion TEAEs after\u00a0\u2265\u00a07\u00a0years of follow\u2010up in patients with Philadelphia chromosome\u2013positive (Ph+) leukemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis of a phase I\/II study and its ongoing extension study included data from patients with chronic phase chronic myeloid leukemia (CML) treated with bosutinib after resistance\/intolerance to imatinib (CP2L) or to imatinib plus dasatinib and\/or nilotinib (CP3L), and those with accelerated\/blast phase CML or acute lymphoblastic leukemia after treatment with, at a minimum, imatinib (ADV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all, 570 patients were treated with bosutinib; median treatment duration was 11.1\u00a0months (range: 0.03\u2010133.1). The incidence of cardiac, vascular, hypertension, and effusion\u2010related TEAEs was 10.9%, 8.8%, 9.1%, and 13.3%, respectively. Few patients had maximum grade 3\u20104 TEAEs (cardiac, 3.9%; vascular, 4.0%; hypertension, 3.0%; effusion, 4.6%). Grade 5 TEAEs occurred in the cardiac (0.7%) and vascular (1.8%) clusters only. In years 5\u20107, fewer than 5% of patients each year had newly occurring cardiac, vascular, hypertension, or effusion TEAEs. The exposure\u2010adjusted TEAE rates (patients with TEAEs\/total patient\u2010year) pooled across CP2L, CP3L, and ADV cohorts were as follows: cardiac, 0.044; vascular, 0.035; hypertension, 0.038; and effusion, 0.056, of which, correspondingly, 0.9%, 1.2%, 0%, and 2.1% required treatment discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The incidence of cardiac, hypertension, vascular, and effusion events was low in patients with Ph+\u00a0CML resistant or intolerant to prior therapy who were treated with bosutinib.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13608","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:36:41Z","timestamp":1614404201000},"page":"808-820","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long\u2010term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome\u2013positive leukemia resistant or intolerant to prior therapy"],"prefix":"10.1111","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"An","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Nick","sequence":"additional","affiliation":[{"name":"Pfizer AG Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[{"name":"Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"additional","affiliation":[{"name":"University of Milano\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum RWTH Aachen Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0780-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31823dec8d"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13716"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23938"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000165"},{"key":"e_1_2_9_8_1","unstructured":"Pfizer Inc.Prescribing Information: BOSULIF (Bosutinib).2019.http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=884(accessed 4 June 2020)"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1466294"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2014.03.003"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24360"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7051"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03802-y"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24155"},{"key":"e_1_2_9_20_1","unstructured":"Bristol\u2010Myers Squibb.Prescribing Information: Sprycel (Dasatinib).2017.https:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf(accessed 29 June 2018)"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188987"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638210"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S108874"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03705-y"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2231-9"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2606"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy019"},{"key":"e_1_2_9_31_1","unstructured":"ARIAD Pharmaceuticals Inc.Prescribing information: ICLUSIG (ponatinib).2017.http:\/\/iclusig.com\/pi(accessed 29 June 2018)"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5932"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13608","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:29:21Z","timestamp":1693416561000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/ejh.13608"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13608","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]},"assertion":[{"value":"2021-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}